GLP-1 FAQ Hub

Most are injections given once weekly (e.g., Wegovy, Mounjaro, Saxenda). One version – Rybelsus – is a daily tablet.

They’ve been used for diabetes for over a decade. Their use for medical weight loss was approved more recently following landmark trials (STEP and SURMOUNT).

They reduce hunger, slow digestion, and stabilise blood sugar, helping your body consume fewer calories naturally.

They’re not suitable if you:

• Are pregnant or breastfeeding
• Have severe gastrointestinal disease
• Have severe liver or kidney disease
• Have severe heart failure

Yes, they’re approved by the MHRA, EMA, and FDA. Side effects are mostly mild and manageable (usually nausea or constipation early on).

Usually yes, but your clinician will review interactions with insulin, sulfonylureas, or oral diabetes agents.

Yes. Keep unopened pens refrigerated. Once in use, they can be stored at room temperature (up to 30 °C) for several weeks.

If within 5 days (for weekly injections), take it when you remember. Otherwise, skip and continue your schedule.

Take oral semaglutide (Rybelsus) on an empty stomach with a small sip of water – then wait 30 minutes before eating or taking other medicines.

Reduced appetite usually appears within 2–4 weeks; visible weight changes follow after 6–8 weeks.

They’re long-term treatments. Stopping usually leads to weight regain unless supported by strong lifestyle changes.

• Eat smaller portions and chew slowly.
• Avoid large or fatty meals during dose escalation.
• Stay hydrated and add fibre gradually.

If you experience severe stomach pain, vomiting, or yellowing of skin or eyes – contact your clinician urgently.

Yes, in moderation. Alcohol can worsen nausea or dehydration.

Most people find energy improves once appetite and sleep normalise. Moderate exercise (walking, resistance training) enhances results.

Appetite returns to baseline and some weight may come back. Continued monitoring and habit change are key to maintaining results.

Yes, studies show reduced liver fat and inflammation in many patients.

Many report fewer food and alcohol cravings and improved confidence once stable on treatment.

Yes, cardiovascular-outcome trials show reduced major cardiac events in people with diabetes.

Medicspot and other regulated clinics offer GLP-1 medications privately for eligible adults, with ongoing clinician monitoring.

Demand is high worldwide. Pharmacies may temporarily limit supply to ensure ongoing treatment for current patients.

Yes, multi-year follow-up data show stable safety with continued clinician oversight.

Yes, under clinical guidance. Doses differ by formulation and should be carefully adjusted.